University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medical Biology
  • Medical Biology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medical Biology
  • Medical Biology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia

    Thumbnail
    Download
    published version (3.483Mb)

    Citations
    Scopus
    Web of Science
    Altmetric
    2
    1
    Author
    McArthur, K; D'Cruz, AA; Segal, D; Lackovic, K; Wilks, AF; O'Donnell, JA; Nowell, CJ; Gerlic, M; Huang, DCS; Burns, CJ; ...
    Date
    2017-08-29
    Source Title
    Oncotarget
    Publisher
    IMPACT JOURNALS LLC
    University of Melbourne Author/s
    Burns, Christopher; Segal, David; Lackovic, Kurt; Huang, David; McArthur, Kate; O'Donnell, Joanne
    Affiliation
    Medical Biology (W.E.H.I.)
    School of Chemistry
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    McArthur, K., D'Cruz, A. A., Segal, D., Lackovic, K., Wilks, A. F., O'Donnell, J. A., Nowell, C. J., Gerlic, M., Huang, D. C. S., Burns, C. J. & Croker, B. A. (2017). Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia. ONCOTARGET, 8 (35), pp.57948-57963. https://doi.org/10.18632/oncotarget.19678.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/256932
    DOI
    10.18632/oncotarget.19678
    Abstract
    Neutropenia represents one of the major dose-limiting toxicities of many current cancer therapies. To circumvent the off-target effects of cytotoxic chemotherapeutics, kinase inhibitors are increasingly being used as an adjunct therapy to target leukemia. In this study, we conducted a screen of leukemic cell lines in parallel with primary neutrophils to identify kinase inhibitors with the capacity to induce apoptosis of myeloid and lymphoid cell lines whilst sparing primary mouse and human neutrophils. We have utilized a high-throughput live cell imaging platform to demonstrate that cytotoxic drugs have limited effects on neutrophil viability but are toxic to hematopoietic progenitor cells, with the exception of the topoisomerase I inhibitor SN-38. The parallel screening of kinase inhibitors revealed that mouse and human neutrophil viability is dependent on cyclin-dependent kinase (CDK) activity but surprisingly only partially dependent on PI3 kinase and JAK/STAT signaling, revealing dominant pathways contributing to neutrophil viability. Mcl-1 haploinsufficiency sensitized neutrophils to CDK inhibition, demonstrating that Mcl-1 is a direct target for CDK inhibitors. This study reveals a therapeutic window for the kinase inhibitors BEZ235, BMS-3, AZD7762, and (R)-BI-2536 to induce apoptosis of leukemia cell lines whilst maintaining immunocompetence and hemostasis.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45689]
    • School of Chemistry - Research Publications [517]
    • Medical Biology - Research Publications [865]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors